➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Merck
McKinsey
Express Scripts
McKesson

Last Updated: June 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for IRX-5183


Email this page to a colleague

« Back to Dashboard

What is the drug development status for IRX-5183?

IRX-5183 is an investigational drug.

There have been 10 clinical trials for IRX-5183. The most recent clinical trial was a Phase 2 trial, which was initiated on October 30th 2017.

The most common disease conditions in clinical trials are Carcinoma, Squamous Cell, Carcinoma, and Head and Neck Neoplasms. The leading clinical trial sponsors are IRX Therapeutics, National Cancer Institute (NCI), and Providence Health & Services.

Recent Clinical Trials for IRX-5183
TitleSponsorPhase
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast CancerBrooklyn ImmunoTherapeutics, LLCPhase 2
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast CancerMerck Sharp & Dohme Corp.Phase 2
Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast CancerProvidence Health & ServicesPhase 2

See all IRX-5183 clinical trials

Clinical Trial Summary for IRX-5183

Top disease conditions for IRX-5183
Top clinical trial sponsors for IRX-5183

See all IRX-5183 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Colorcon
Merck
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.